Article: Depression treatment shows promise for major depressive disorder.

2003 DEC 22 - (NewsRx.com & NewsRx.net) -- There were no significant tolerability issues attributable to chronic vs. acute use of the investigational agent Cymbalta; patients who tolerated Cymbalta during the early period of the trial were likely to tolerate long-term dosing. Of the patients in the study, 520 remained on Cymbalta for at least 360 days, yielding approximately 808 patient-years of total exposure.

In addition, patients in the study who responded to treatment with Cymbalta had a high probability of achieving remission. Remission rates at 52 weeks in this study were close to response rates (81.8% and 89.1%, respectively), implying that patients who ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!